Cargando…

Clinical Implications of Intestinal Barrier Damage in Psoriasis

BACKGROUND: An increasing amount of evidence suggests an association between increased intestinal permeability and the pathogenesis of chronic inflammatory diseases. However, the clinical significance of gut barrier dysfunction in psoriasis remains to be established. OBJECTIVE: To evaluate whether t...

Descripción completa

Detalles Bibliográficos
Autores principales: Sikora, Mariusz, Stec, Albert, Chrabaszcz, Magdalena, Giebultowicz, Joanna, Samborowska, Emilia, Jazwiec, Radoslaw, Dadlez, Michal, Olszewska, Malgorzata, Rudnicka, Lidia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7851376/
https://www.ncbi.nlm.nih.gov/pubmed/33542642
http://dx.doi.org/10.2147/JIR.S292544
_version_ 1783645614072922112
author Sikora, Mariusz
Stec, Albert
Chrabaszcz, Magdalena
Giebultowicz, Joanna
Samborowska, Emilia
Jazwiec, Radoslaw
Dadlez, Michal
Olszewska, Malgorzata
Rudnicka, Lidia
author_facet Sikora, Mariusz
Stec, Albert
Chrabaszcz, Magdalena
Giebultowicz, Joanna
Samborowska, Emilia
Jazwiec, Radoslaw
Dadlez, Michal
Olszewska, Malgorzata
Rudnicka, Lidia
author_sort Sikora, Mariusz
collection PubMed
description BACKGROUND: An increasing amount of evidence suggests an association between increased intestinal permeability and the pathogenesis of chronic inflammatory diseases. However, the clinical significance of gut barrier dysfunction in psoriasis remains to be established. OBJECTIVE: To evaluate whether there are differences in disease activity, the severity of gastrointestinal symptoms and the blood concentration of bacterial metabolites in psoriatic patients with a normal and altered intestinal barrier. PATIENTS AND METHODS: Gut barrier integrity was assessed with the serum concentrations of claudin-3, a modulator of intestinal tight junctions and an intestinal fatty acid-binding protein, a marker of enterocyte damage. Gastrointestinal symptoms were evaluated with a validated questionnaire. The concentration of trimethylamine N-oxide (TMAO), a gut microbiota-associated metabolite, was measured with high-performance liquid chromatography. RESULTS: One hundred and fourteen patients with psoriasis were finally enrolled in the study – 68 with an altered gut barrier and 46 with a properly functioning intestinal barrier. Patients with an altered gut barrier showed a significantly higher score in the Gastrointestinal Symptom Rating Scale (3.20 vs 1.46, p<0.001). Moreover, patients with psoriasis and a disrupted intestinal barrier demonstrated a higher disease activity (PASI: 19.7 vs 10.3, p<0.001) and systemic inflammatory parameters (neutrophil-to-lymphocyte ratio: 2.86 vs 1.71, p<0.001; C-reactive protein 3.76 vs 1.92; p<0.05). The marker of bacterial translocation was significantly higher in psoriatic patients with damaged gut integrity (TMAO: 375.7±51.9 vs 119.4±27.5 ng/mL; p<0.05). CONCLUSION: The altered gut barrier in psoriasis is associated with gastrointestinal symptoms, systemic inflammatory profile and the increased blood concentration of gut microbiota-derived metabolite – TMAO. Intestinal barrier modulation represents a new promising therapeutic approach.
format Online
Article
Text
id pubmed-7851376
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-78513762021-02-03 Clinical Implications of Intestinal Barrier Damage in Psoriasis Sikora, Mariusz Stec, Albert Chrabaszcz, Magdalena Giebultowicz, Joanna Samborowska, Emilia Jazwiec, Radoslaw Dadlez, Michal Olszewska, Malgorzata Rudnicka, Lidia J Inflamm Res Original Research BACKGROUND: An increasing amount of evidence suggests an association between increased intestinal permeability and the pathogenesis of chronic inflammatory diseases. However, the clinical significance of gut barrier dysfunction in psoriasis remains to be established. OBJECTIVE: To evaluate whether there are differences in disease activity, the severity of gastrointestinal symptoms and the blood concentration of bacterial metabolites in psoriatic patients with a normal and altered intestinal barrier. PATIENTS AND METHODS: Gut barrier integrity was assessed with the serum concentrations of claudin-3, a modulator of intestinal tight junctions and an intestinal fatty acid-binding protein, a marker of enterocyte damage. Gastrointestinal symptoms were evaluated with a validated questionnaire. The concentration of trimethylamine N-oxide (TMAO), a gut microbiota-associated metabolite, was measured with high-performance liquid chromatography. RESULTS: One hundred and fourteen patients with psoriasis were finally enrolled in the study – 68 with an altered gut barrier and 46 with a properly functioning intestinal barrier. Patients with an altered gut barrier showed a significantly higher score in the Gastrointestinal Symptom Rating Scale (3.20 vs 1.46, p<0.001). Moreover, patients with psoriasis and a disrupted intestinal barrier demonstrated a higher disease activity (PASI: 19.7 vs 10.3, p<0.001) and systemic inflammatory parameters (neutrophil-to-lymphocyte ratio: 2.86 vs 1.71, p<0.001; C-reactive protein 3.76 vs 1.92; p<0.05). The marker of bacterial translocation was significantly higher in psoriatic patients with damaged gut integrity (TMAO: 375.7±51.9 vs 119.4±27.5 ng/mL; p<0.05). CONCLUSION: The altered gut barrier in psoriasis is associated with gastrointestinal symptoms, systemic inflammatory profile and the increased blood concentration of gut microbiota-derived metabolite – TMAO. Intestinal barrier modulation represents a new promising therapeutic approach. Dove 2021-01-27 /pmc/articles/PMC7851376/ /pubmed/33542642 http://dx.doi.org/10.2147/JIR.S292544 Text en © 2021 Sikora et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Sikora, Mariusz
Stec, Albert
Chrabaszcz, Magdalena
Giebultowicz, Joanna
Samborowska, Emilia
Jazwiec, Radoslaw
Dadlez, Michal
Olszewska, Malgorzata
Rudnicka, Lidia
Clinical Implications of Intestinal Barrier Damage in Psoriasis
title Clinical Implications of Intestinal Barrier Damage in Psoriasis
title_full Clinical Implications of Intestinal Barrier Damage in Psoriasis
title_fullStr Clinical Implications of Intestinal Barrier Damage in Psoriasis
title_full_unstemmed Clinical Implications of Intestinal Barrier Damage in Psoriasis
title_short Clinical Implications of Intestinal Barrier Damage in Psoriasis
title_sort clinical implications of intestinal barrier damage in psoriasis
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7851376/
https://www.ncbi.nlm.nih.gov/pubmed/33542642
http://dx.doi.org/10.2147/JIR.S292544
work_keys_str_mv AT sikoramariusz clinicalimplicationsofintestinalbarrierdamageinpsoriasis
AT stecalbert clinicalimplicationsofintestinalbarrierdamageinpsoriasis
AT chrabaszczmagdalena clinicalimplicationsofintestinalbarrierdamageinpsoriasis
AT giebultowiczjoanna clinicalimplicationsofintestinalbarrierdamageinpsoriasis
AT samborowskaemilia clinicalimplicationsofintestinalbarrierdamageinpsoriasis
AT jazwiecradoslaw clinicalimplicationsofintestinalbarrierdamageinpsoriasis
AT dadlezmichal clinicalimplicationsofintestinalbarrierdamageinpsoriasis
AT olszewskamalgorzata clinicalimplicationsofintestinalbarrierdamageinpsoriasis
AT rudnickalidia clinicalimplicationsofintestinalbarrierdamageinpsoriasis